MD
MDDVF.US Medical Developments International Limited
- Market cap
- USD 30.7M
- P/E
- -
- P/B
- 0.80x
- ROE
- 1.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is MDDVF.US undervalued?
Graham numberThe Graham number of Medical Developments International Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Medical Developments International Limited fundamental analysis
No fundamental analysis for Medical Developments International Limited yet.
Medical Developments International Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Medical Developments International Limited
Medical Developments International Limited provides emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The company also supplies respiratory pr…
Full company profileMedical Developments International Limited financial statements
Medical Developments International Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 18.3M | 17.5M | 20.9M | 22.5M | 25.3M | 21.9M | 32.3M | 33.1M | 39.1M | 42.5M |
| Gross Profit | 12.6M | 12.4M | 14.2M | 13.7M | 16.7M | -3.06M | -2.52M | 24.4M | 29.4M | 12.0M |
| Operating Income | 3.50M | 2.07M | 3.17M | 1.87M | -5.24M | -15.7M | -14.4M | -11.0M | 3.07M | 1.06M |
| EBITDA | 3.80M | 2.15M | 3.88M | 3.03M | -11.3M | -12.9M | -4.28M | -29.4M | 3.34M | 3.74M |
| Net Income | 1.82M | 243K | 1.04M | 379K | -12.6M | -12.4M | -5.61M | -41.0M | 94.0K | 625K |
| EPS | 0.03 | 0.00 | 0.02 | 0.01 | -0.18 | -0.17 | -0.07 | -0.47 | 0.00 | 0.01 |
| Balance Sheet | ||||||||||
| Total Assets | 41.8M | 49.5M | 84.8M | 94.9M | 100M | 101M | 109M | 59.2M | 66.4M | 68.5M |
| Total Liabilities | 20.2M | 28.5M | 40.2M | 51.5M | 31.9M | 44.1M | 28.2M | 13.4M | 11.3M | 12.8M |
| Shareholders' Equity | 21.6M | 21.0M | 44.6M | 43.3M | 68.3M | 57.3M | 81.3M | 45.7M | 55.1M | 55.7M |
| Cash & Short-term Investments | 1.69M | 794K | 25.6M | 15.5M | 36.3M | 20.4M | 24.7M | 9.74M | 17.8M | 21.3M |
| Total Debt | 429K | 9.25M | 182K | 3.36M | 3.05M | 2.81M | 2.56M | 2.29M | 1.99M | 1.66M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 4.01M | 1.79M | 21.3M | 601K | -8.81M | -10.7M | -16.5M | -10.8M | -43.0K | 5.74M |
| Capital Expenditure | 4.35M | 2.06M | 1.49M | 8.90M | 6.56M | 5.21M | 7.67M | 3.17M | 443K | 480K |
| Free Cash Flow | -342K | -268K | 19.8M | -8.30M | -15.4M | -15.9M | -24.2M | -13.9M | -486K | 5.26M |
| Ratios | ||||||||||
| ROE | 8.4% | 1.2% | 2.3% | 0.9% | -18.4% | -21.7% | -6.9% | -89.6% | 0.2% | 1.1% |
| ROA | 4.4% | 0.5% | 1.2% | 0.4% | -12.5% | -12.2% | -5.1% | -69.3% | 0.1% | 0.9% |
| Net Profit Margin | 9.9% | 1.4% | 5.0% | 1.7% | -49.7% | -56.5% | -17.3% | -123.7% | 0.2% | 1.5% |
| Debt to Equity | 0.02x | 0.44x | 0.00x | 0.08x | 0.04x | 0.05x | 0.03x | 0.05x | 0.04x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Medical Developments International Limited dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Sep 4, 2013
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 2.07M | 0.03 | 544.9% |
| 2019 | USD 1.72M | 0.03 | 165.4% |
| 2018 | USD 1.24M | 0.02 | 509.9% |
| 2017 | USD 1.24M | 0.02 | 68.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 63:62 on Feb 9, 2023.
Who owns Medical Developments International Limited
- Insiders 25.16%
- Institutions 24.04%
- Public & others 50.81%
- Shares outstanding 113M
- Free float 73.6M
Medical Developments International Limited company profile
- Company name
- Medical Developments International Limited
- Ticker
- MDDVF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- June
- Address
- 4 Caribbean Drive, Scoresby, VIC, Australia, 3179
- Phone
- 61 3 9547 1888
- Website
- medicaldev.com
About Medical Developments International Limited
Medical Developments International Limited provides emergency medical solutions in Australia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It manufactures and distributes Penthrox, a fast-acting trauma and emergency pain relief product used in hospital emergency departments, ambulance services, sports medicine, and for analgesia during short surgical procedures. The company also supplies respiratory products, including space chambers, peak flow meters, portable nebulizers, and silicone face masks to aid sufferers of asthma and chronic obstructive pulmonary disease. Medical Developments International Limited was founded in 1972 and is headquartered in Scoresby, Australia.
Medical Developments International Limited management
7- Ms. Anita JamesInterim CEO & CFO
- Ms. Anastasia TanHead of Operations & Supply Chain
- Ms. Tara Eaton L.L.B., L.L.M.Chief Corporate & People Officer and Company Secretary
- Wayne PearceHead of Production
- Ms. Julianne AlexanderHead of Medical Affairs, Regulatory Affairs & Clinical Development
- Mr. Benson LeeHead of Commercial Operations
- Ms. Victoria SowemimoHead of Quality